Serotonin 5-HT2A receptor antagonists in the treatment of insomnia: Present status and future prospects

Drugs of Today

Volumn 46, Issue 3, 2010, Pages 183-193

  Monti, J M ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; 4 AMINOBUTYRIC ACID A RECEPTOR; APD 125; BENZODIAZEPINE DERIVATIVE; BROTIZOLAM; EPLIVANSERIN; ESZOPICLONE; FLUNITRAZEPAM; FLURAZEPAM; GABOXADOL; HYPNOTIC AGENT; IMIDAZOPYRIDINE DERIVATIVE; INDIPLON; MIDAZOLAM; NITRAZEPAM; PIMAVANSERIN; PYRAZOLOPYRIMIDINE DERIVATIVE; QUAZEPAM; RITANSERIN; SEGANSERIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

BEDTIME DOSAGE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EVENING DOSAGE; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; INVERSE AGONISM; MAJOR DEPRESSION; NEUROMODULATION; NONHUMAN; NONREM SLEEP; PATHOPHYSIOLOGY; PREVALENCE; REM SLEEP; REVIEW; SLEEP; SLOW WAVE SLEEP; TRANQUILIZING ACTIVITY; WAKEFULNESS;

ADULT; ANIMALS; BENZODIAZEPINES; HUMANS; HYPNOTICS AND SEDATIVES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN ANTAGONISTS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 77954120696     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.3.1437247     Document Type: Review

References (75)

1. Renger, J.J. Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders. Curr Top Med Chem 2008, 8(11): 937-53.
2. Wafford, K.A., Ebert, B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 2008, 7(6): 530-40. (Pubitemid 351767120)
3. Landolt, H.P., Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009, 29(9): 1795-809.
4. Rechtschaffen, A., Kales, A. A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. National Institute of Health Publ. 204: Washington D.C., 1968.
5. rd ed., 15-25.
6. Adam, K., Oswald, I. Protein synthesis, body renewal and the sleep-wake cycle. Clin Sci 1983, 65(6): 561-67.
7. Shneerson, J.M. Nature of sleep and its disorders. In: Handbook of Sleep Medicine. J.M. Shneerson (Ed.). Blackwell Science: Oxford 2001, 1-15.
8. Shapiro, C.M., Flanigan, M.J. Functions of sleep. In: ABC of Sleep Disorders. C.M. Shapiro (Ed.) BMJ Publishing Group: London 1993, 5-7.
9. Wolkove, N., Elkholy, O., Baltzan, M., Palayew, M. Sleep and aging. Part 1: Sleep disorders commonly found in older people. CMAJ 2007, 176(9): 1299-304.
10. Monti, J.M., Monti, D. Human Sleep. In: Sleep and Quality of Life in Clinical Medicine. J.C. Verster, S.R. Pandi-Perumal, D.L. Streiner (Eds.). Humana: Totowa, NJ 2008, 29-36.
11. Ancoli-Israel, S., Ayalon, L., Salzman, C. Sleep in the elderly: Normal variations and common sleep disorders. Harv Rev Psychiatry 2008, 16(5): 279-86.
12. National Sleep Foundation. 2003 Sleep in America Poll. At http://www.sleepfoundation.org.
13. Thorpy, M.J., Ahmed, IM. Approach to the patient with a sleep complaint. In: Sleep Disorders - Diagnosis and Therapeutics. S.R. Pandi-Perumal, J.C. Verster, J.M. Monti, M. Lader, S.Z. Langer (Eds.). Humana: Totowa, N.J.2008, 21-33.
14. National Institutes of Health. NIH statement regarding the treatment of insomnia. State of the Science Conference Statement: Manifestations and management of chronic insomnia in adults. Sleep 2005, 28: 1049-57.
15. nd edition.
16. Lichstein, K.L. Secondary insomnia. In: Treatment of Late-Life Insomnia. K.L. Lichstein, C.M. Morin (Eds.). Sage Publications: London 2000, 297-319.
17. Harvey, S.C. Hypnotics and sedatives. In: The Pharmacological Basis of Therapeutics. A. Goodman-Gilman, L.S. Goodman, A. Gilman (Eds.). MacMillan: New York 1980, 6th ed., 339-76.
18. Möhler, H. GABA-A-benzodiazepine receptors as targets for new hypnotics. In: Sleep Disorders - Diagnosis and Therapeutics. S.R. Pandi-Perumal, J.C. Verster, J.M. Monti, M. Lader, S.Z. Langer (Eds.). Informa: London 2008, 206-19.
19. Monti, J.M., Monti, D. Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics. In: Clinical Pharmacology of Sleep. S.R. Pandi-Perumal, J.M. Monti (Eds.) Birkhauser Verlag: Basel 2006, 207-23.
20. Lundahl, J., Staner, L., Staner, C., Loft, H., Deacon, S. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology 2007, 195(1): 139-46.
21. A receptor. CNS Spectrums 2005, 10: 20.
22. A receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005, 14: 601-18.
23. Greenblatt, D.J. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 1991, 52(Suppl.): 4-10.
24. Drover, D.R. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004, 43(4): 227-38.
25. Monti, J.M., Pandi-Perumal, S.R., Langer, S.Z. Zolpidem: its use in the treatment of sleep disorders. In: Sleep Disorders - Diagnosis and Therapeutics. S.R. Pandi-Perumal, J.C. Verster, J.M. Monti, M. Lader, S.Z. Langer (Eds.). Informa: London 2008a, 295-323.
26. Carlson, J.N., Haskew, R., Wacker, J., Maisonneuve, I.M., Glick, S.D., Jerussi, T.P. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 2001, 415(2-3): 181-9.
27. Sanger, D.J. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004, 18(Suppl. 1): 9-15.
28. Foster, A.C., Pelleymounter, M.S., Cullen, M.J. et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exptl Ther 2004, 311(2): 547-59.
29. Kales, A, Kales, J.D. Evaluation and Treatment of Insomnia. Oxford University Press: New York 1984, 3-324.
30. Pecknold, J., Wilson, R, Le Morvan, P. Long-term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 1990, 5(Suppl. 2): 57-67.
31. Musch B., Maillard, F. Zopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychopharmacol 1990, 5(Suppl. 2): 147-58.
32. Zammit, G.K., McNabb, L.J., Caron, J., Amato, D.A., Roth, T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004, 20(12): 1979-91.
33. Monti, J.M., Pandi-Perumal, S.R. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 2007, 3(4): 441-53.
34. Monti, J.M., Spence, D.W., Pandi-Perumal, S.R., Langer, S.Z., Hardeland, R. Pharmacotherapy of insomnia: Focus on zolpidem extended release. Clin Med Ther 2009, 1: 123-40.
35. Walsh, J.K., Vogel, G.W., Scharf, M., et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000, 1(1): 41-9.
36. Heydorn, W.E. Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia. Exp Opin Invest Drugs 2000, 9(4): 841-58.
37. Neubauer, D.N. Indiplon: the development of a new hypnotic. Exp Opin Invest Drugs 2005, 14(10): 1269-76.
38. Trulson, M.E., Jacobs, B.L. Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res 1979, 163(1): 135-50.
39. Monti, J.M., Jantos, H., Monti, D. Serotonin and sleep-wake regulation. In: Neurochemistry of Sleep and Wakefulness. J.M. Monti, S.R. Pandi-Perumal, C.M. Sinton (Eds.). Cambridge University Press: Cambridge, 2008b, 244-79.
40. Hannon, J., Hoyer, D. Molecular biology of 5-HT receptors. In: J.M. Monti, S.R. Pandi-Perumal, B.L. Jacobs, D.J. Nutt (Eds.). Serotonin and Sleep: Molecular, Functional and Clinical Aspects. Birkhauser Verlag: Basel 2008, 155-82.
41. 2A receptor in the central nervous system of adult rat. J Comp Neurol 1999, 409(2): 187-209.
42. Nichols, D.E., Nichols, C.D. Serotonin receptors. Chem Rev 2008, 108(5): 1614-41.
43. 2A receptors. J Neurosci 2005, 25(49): 11231-38.
44. 2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994, 33(3-4): 411-21. (Pubitemid 124015963)
45. 2A receptor antagonist, MDL, 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995, 273(3): 273-9.
46. Fink, K.B, Göthert, M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007, 59(4): 360-417.
47. 2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 1987, 137(1): 145-6.
48. 2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology 1989, 97(4): 436-42.
49. Monti, J.M., Orellana, C., Boussard, M. et al. 5-HT receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 8-OH-DPAT increase wakefulness in the rat. Biogen Amines, 1990, 7: 145-51.
50. 2 receptor subtype specific drugs. Eur J Pharmacol 1995, 282(1-3): 39-55.
51. 2 antagonists on rapid eye movement sleep in rats. Brain Res 1989, 485(2): 294-300.
52. 2 antagonist ritanserin of sleep-waking cycle in the rat. Physiol Behav 1991, 41(1): 241-3.
53. Coenen, A.M. L., Ates, N. Skarsfeldt, T., Luijtelaar, E.L.J.M. Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns, and epileptic activity in rats. Pharmacol Biochem Behav 1995, 51(2-3): 353-7.
54. Kirov, R., Moyanova, S. Age-dependent effect of ketanserin on the sleep-waking phases in rats. Int J Neurosci 1998, 93(3-4): 257-64.
55. Kirov, R., Moyanova, S. Age-related effect of ritanserin on the sleep-waking phases in rats. Int J Neurosci 1998, 93(3-4): 265-78.
56. 6 receptor antagonists promote sleep in the rats. Sleep 2008, 31(1): 34-44.
57. 2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol 2006, 553(1-3): 163-70.
58. Idzikowski, C., Mills, F.J., Glennard, R. 5-Hydroxytryptamine-2- antagonist ritanserin increases human slow wave sleep. Brain Res 1986, 378(1): 164-8.
59. Estevez, F., Giusti, M., Monti, J.M. Ritanserin pharmacokinetics in abstinent chronic alcoholics. Medicina (B. Aires) 1995, 55(1): 39-44.
60. Idzikowski, C., Cowen, P.J., Mills, F.J. The effect of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology 1987, 93(4): 416-20.
61. Idzikowski, C. Mills, F.J., James, R.J. A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol 1991, 31(2): 193-6.
62. Kamali, F., Stansfield, S.C., Ashton, C.H., Hammond, G.L., Emanuel, M.B. Rawlins, M.D. Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. Psychopharmacology 1992, 108(1-2): 213-7.
63. Idzikowski, C. The effects of ritanserin and seganserin on human slow wave sleep. In: Slow Wave Sleep - Physiological, Pathophysiological and Functional Aspects. A. Wauquier, C. Dugovic, M. Radulovacki (Eds.). Raven Press: New York 1989, 197-215.
64. 2C receptors. Neuropharmacology 1994, 33(3-4): 467-71.
65. 2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 1989, 171(2-3): 207-18.
66. 2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 1990, 101(4): 568-9.
67. Landolt, H.P., Viola, M., Burgess, H.J., Finelli, L.A., Cattelin, F., Achermann, P., Borbely, A.A. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999, 21(3): 455-66.
68. 2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008, 9(18): 3251-9.
69. Adam, K., Oswald, I. Effects of repeated ritanserin on middle-aged poor sleepers. Psychopharmacology 1989, 99(2): 219-21.
70. Ruiz-Primo, E., Haro, R., Valencia, M. Polysomnographic effects of ritanserin in insomniacs. A crossed double-blind controlled study. Sleep Res 1989, 18: 72.
71. Monti, J.M., Alterwain, P., Estévez, F., Alvariño, F., Giusti, M., Olivera, S., Labraga, P. The effects of ritanserin on mood and sleep in abstinent alcoholic patients. Sleep 1993, 16(7): 647-54.
72. da Roza Davis, J.M., Sharpley, A.L., Cowen, P.J. Slow wave sleep and 5-HT2 receptor sensitivity in generalised anxiety disorder. Psychopharmacology 1992, 108(3): 387-9.
73. Paiva, T., Arriaga, F., Wauquier, A., Lara, E., Largo, R., Leitao, J.N. Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology 1988, 96(3): 395-9.
74. Staner, L., Kempenaers, C., Simonnet, M.P., Fransolet, L., Mendlewicz, J. 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 1992, 86(2): 133-7.
75. Seiden, D.J., Hull, S.G., Erman, M. et al. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 2008, 31(12): 1663-71.